Skip to main content
. 2018 Dec 4;2(4):pky055. doi: 10.1093/jncics/pky055

Table 2.

Association between prolactin levels (ng/mL) and mammographic density, described using cBIRADS, stratified by menopausal and case-control status

cBIRADS
% increase per cBIRADS*
Category 1 2 3 4 Ptrend*
Premenopausal women
 No. of cases/controls 5/21 42/107 113/202 67/68
 Prolactin, ng/mL, geometric mean, all women, multivariable model 13.3 15.3 15.9 16.8 8.2 .12
 Prolactin, ng/mL, geometric mean, controls, multivariable model 12.7 14.9 15.5 15.7 7.5 .28
 Prolactin, ng/mL, geometric mean, cases, multivariable model 19.0 17.1 16.5 17.7 −2.1 .82
Postmenopausal women
 No. of cases/controls 62/189 224/475 172/273 14/25
 Prolactin, ng/mL, geometric mean, all women, multivariable model 10.8 11.1 11.9 11.9 3.3 .03
 Prolactin, ng/mL, geometric mean, controls, multivariable model 11.1 11.0 11.8 11.4 1.0 .31
 Prolactin, ng/mL, geometric mean, cases, multivariable model 9.7 11.1 11.9 13.1 10.6 .03
*

Average percentage change in prolactin level per category increase in mammographic density by computer-generated breast imaging reporting and data system score (cBIRADS). P value (two-sided) based on F-test with natural log-transformed prolactin (ng/mL), continuous, and cBIRADS as dependent variable. cBIRADS = computer-generated breast imaging reporting and data system score.

Adjusted for age and body mass index at blood draw, benign breast disorder (no, yes), breast cancer in family (no, yes), smoking status (never, previous, or current smoker), age at menarche, and number of births (0, 1, 2, or ≥3).

Adjusted for age and body mass index at blood draw, benign breast disorder (no, yes), breast cancer in family (no, yes), smoking status (never, previous, or current smoker), age at menarche, number of births (0, 1, 2, or ≥3), and ever use of hormone replacement therapy.